Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of “Hold” from Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been given an average rating of “Hold” by the five ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $4.00.

MCRB has been the topic of several research analyst reports. The Goldman Sachs Group reduced their price objective on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a report on Friday, March 14th. Chardan Capital reissued a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research note on Thursday, March 20th. Finally, StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, April 10th.

Seres Therapeutics Stock Performance

Shares of Seres Therapeutics stock opened at $0.66 on Tuesday. Seres Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $1.53. The firm has a market capitalization of $115.65 million, a price-to-earnings ratio of -2.88 and a beta of 2.54. The stock has a 50 day moving average of $0.72 and a 200 day moving average of $0.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vontobel Holding Ltd. boosted its position in Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 543,469 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 117,107 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the period. FMR LLC increased its holdings in Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares during the period. Finally, State Street Corp increased its holdings in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.